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Histone acetylation plays an important role in the
modulation of chromatin structure associated with tran-
scriptional activation (Grunstein, 1997; Mizzen and Allis,Summary
1998; Struhl, 1998). The mechanism by which acetylation
of core histones influences transcriptional activation isNucleosomal histone modification is believed to be
uncertain. It is, nonetheless, proposed that acetylationa critical step in the activation of RNA polymerase
of the amino-terminal lysine-rich histone tails promotesII±dependent transcription. p300/CBP and PCAF his-
destabilization of histone±DNA interactions in the nucleo-tone acetyltransferases (HATs) are coactivators for
some, resulting in increased accessibility of the chroma-several transcription factors, including nuclear hor-
tin to the transcription machinery. In agreement with
mone receptors, p53, and Stat1a, and participate in
biochemical and genetic studies, recent crystallographic
transcription by forming an activation complex and
analysis of nucleosomes also suggests a role for the
by promoting histone acetylation. The adenoviral E1A
histone tails in higher order chromatin structure (Luger et
oncoprotein represses transcriptional signaling by
al., 1997). The modulation of gene expression by histone
binding to p300/CBP and displacing PCAF and p/CIP acetylation implies that acetylation may be targeted to
proteins from the complex. Here, we show that E1A specific genes or chromosomal domains (Utley et al.,
directly represses the HAT activity of both p300/CBP 1998). A simple but attractive hypothesis is that the
and PCAF in vitro and p300-dependent transcription targeted histone acetylation is achieved by recruitment
in vivo. Additionally, E1A inhibits nucleosomal histone of acetyltransferases to the signal responsive promot-
modifications by the PCAF complex and blocks p53 ers. Recent observations that transcription cofactors,
acetylation. These results demonstrate the modula- including p300/CBP, PCAF, ACTR, SRC-1, yeast and
tion of HAT activity as a novel mechanism of transcrip- human GCN5, and the TAF250 subunit of TFIID, are
tional regulation. intrinsic histone acetyltransferases (HATs) and are re-
cruited in a signal-dependent manner are consistent
Introduction with this model (Brownell et al., 1996; Mizzen et al., 1996;
Ogryzko et al., 1996; Yang et al., 1996; Chen et al., 1997;
The mechanism of transcriptional regulation by coacti- Spencer et al., 1997). A potential PCAF coactivation
vator proteins, including p300/CBP and PCAF, has been complex consisting of histone H4-, H3-, and H2B-like
a focus of intense study. The importance of p300/CBP subunits but free of p300/CBP has also been shown to
in the regulation of RNA polymerase II transcription is have HAT activity (Ogryzko et al., 1998). While the role
supported by their ability to potentiate the activity of a of the PCAF complex during transactivation is unknown,
large number of transcription factors, including nuclear the presence of histone-like subunits implies an archi-
hormone receptors, p53, and Stat1a (Chakravarti et al., tectural role in the maintenance of an active chromatin.
1996; Janknecht and Hunter, 1996; Zhang et al., 1996; These results along with the recent reports that the ace-
Gu et al., 1997). Recent mechanistic studies demon- tylase activities of p300/CBP, PCAF, and GCN5 are re-
strate that p300/CBP can either be recruited to promot- quired for their coactivator function in vivo imply that
ers by direct interaction with transcription factors or as the cofactor-mediated regulation of gene expression
part of a complex containing other cofactors such as and chromatin modification may be tightly linked (Puri
PCAF, SRC-1, and the ACTR/p/CIP group of proteins et al., 1997; Korzus et al., 1998; Kuo et al., 1998; Wang
et al., 1998).
The adenoviral E1A oncoprotein inhibits cellular differ-‖ To whom correspondence should be addressed (e-mail: evans@
salk.edu [R. M. E.] and debu@pharm.med.upenn.edu [D. C.]). entiation, in part, by interfering with the function of the
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Figure 1. E1A Inhibits the HAT Activity of p300
(A) (Left) The cartoon depicts E1A and relevant functional domains of p300 (see text for details). (Right) 1.9 pmol of p300 were incubated with
no E1A (lanes 1, 2, and 6), E1A213S (lane 3), GST-E1A-13S (lane 4), or GST-E1A-12S (lane 5) prior to the addition of histone H3 and H4 (lanes
2±6). Reaction products were separated by SDS-10%±20% gradient PAGE and analyzed by phosphorimager. % of activity remaining and %
inhibition of acetylation were calculated by determining the radioactivity in individual histone bands and using the values of histone H3 and
H4 acetylation in lanes 2 or 6 as 100% (for % activity remaining) and 0% (for % inhibition of acetylation), respectively. GST alone or GST
fusion of a nonrelated protein had no effect on the assay system. Data from two separate experiments (lanes 1±4, and lanes 5 and 6) are
presented.
(B) The mode of action of E1A. Acetylation assays were similar to that of Figure 1A. Lane 1 represents uninhibited p300-HAT activity. In lane
2, p300 was incubated with E1A-13S for 10 min prior to the addition of histones. In lane 3, histones and E1A were added simultaneously to
p300, and reaction was continued. In lane 4, E1A-13S was added 10 min after the acetylation reaction with histones and p300.
(C and D) Inhibition of p300-mediated acetylation of histone H4 (C) and H3 (D) by E1A. 1.9 pmol (80 nM) of p300 was incubated in the presence
or absence of increasing amounts of GST-E1A-13S for 5 min before the addition of 50 pmol (2 mM) of purified histone H4 (C) or H3 (D).
Reaction products were separated by SDS-PAGE and analyzed by phosphorimager. The radioactivity in individual histone band was determined
and % activity remaining calculated for each assay point using the value of p300-mediated acetylation of histone H4 (C) or H3 (D) in the
absence of E1A as 100%. The IC50 values were calculated by determining the concentration of E1A needed to promote 50% inhibition of
acetylation.
p300/CBP and retinoblastoma (pRb) proteins (Dyson and proteins p107 and p130 (Dyson and Harlow, 1992;
Moran, 1993; Wang et al., 1993). The mechanisms byHarlow, 1992; Moran, 1993; Eckner et al., 1994; Arany et
al., 1995). Mutational analyses have demonstrated that which E1A interferes with p300/CBP function are still
unclear. One proposed mechanism is that binding ofthe N terminus (amino acids 1±25) and the conserved
region 1 (CR1; amino acids 35±76) of E1A play important E1A to p300/CBP disrupts the p300/CBP±PCAF and
p300/CBP±p/CIP coactivation complexes (Yang et al.,roles in p300/CBP binding. The conserved region 2 (CR2;
amino acids 121±138) and the amino-terminal part of 1996; Kurokawa et al., 1998). In support of the above
observation, it was demonstrated that overexpressionCR1 are necessary for binding to pRb and the related
E1A Inhibits Acetyltransferase Activity
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Figure 2. Mapping of the HAT-Inhibitory Do-
main of E1A
(A) Analysis of the N-terminal deletion mu-
tants of E1A. (Left) Names and functional do-
mains of the wild-type and mutant E1A pro-
teins are shown. (Right) Summary of the
results is presented. Purified GST fusions of
wild-type E1A (construct 1) or the progressive
N-terminal deletion mutants of E1A (con-
structs 2±6) were incubated with p300 prior
to the separate addition of either purified his-
tone H4 or H3. After incubation, products
were subjected to SDS-10%±20% PAGE fol-
lowed by phosphorimager analysis. % inhibi-
tion (right panels) was calculated as de-
scribed in Figure 1, using the value of
uninhibited acetylation reaction as 0%. Data
from two separate experiments are pre-
sented.
(B) Analysis of the C-terminal deletion mu-
tants of E1A. The HAT inhibitory activity of the
GST fusion of the C-terminal deletion mutants
was determined essentially as described in
Figure 2A, except that the GST fusion of the
C-terminal deletion mutants of E1A was used.
of PCAF in cells could counteract the mitogenic activity et al., 1996). Preincubation of either purified wild-type
E1A-13S (lane 3), GST-E1A-13S (lane 4), or GST-E1A-of E1A (Yang et al., 1996). However, since the HAT activ-
ity of PCAF is not required for all p300/CBP-dependent 12S (lane 5) with p300 resulted in dramatic (70%±90%)
inhibition of histone H4 and H3 acetylation (Figure 1A,transcription, PCAF displacement alone may not be suf-
ficient to fully account for the repressive effects of E1A bottom panels). Together, these results suggest that
E1A can not only bind p300 but also can inhibit its intrin-(Puri et al., 1997; Korzus et al., 1998). Furthermore, the
PCAF-dependent transcription is also inhibited by E1A sic HAT activity. An order of addition experiment was
carried out to demonstrate that E1A must be present at(Puri et al., 1997). These results demonstrate the com-
plex nature of E1A action and suggest additional mecha- the beginning of the reaction. A standard uninhibited
p300-mediated histone acetylation reaction is shown innisms other than PCAF displacement for the inhibitory
activity of E1A. The proximity of the E1A-binding site to Figure 1B, lane 1. Incubation of p300 with E1A prior to
the addition of histones, as expected, led to severethe HAT domain of p300/CBP and the ability of E1A to
interfere with both p300/CBP and PCAF function led inhibition of histone acetylation (lane 2). Interestingly,
simultaneous addition of a 1:1 molar ratio of E1A andus to consider the additional possibility that E1A may
modulate the enzymatic activity of both p300/CBP and histones to p300 also resulted in the inhibition of the
HAT activity (compare lane 2 with lane 3), indicating thePCAF. Here, we provide biochemical, mutational, and
functional data demonstrating E1A is a potent inhibitor rapid nature of E1A action. However, if E1A was added
10 min after the standard acetylation reaction, little or noof the acetyltransferase activity of p300/CBP, free PCAF,
as well as the PCAF complex in vitro and that this inhibi- inhibition was observed (lane 4, and Figure 1B, bottom
panels). These experiments indicate E1A functions astory activity is necessary for E1A function in vivo.
an active acetylase inhibitor and not as a deacetylase.
We note that histone H4 acetylation is more sensitiveResults
to E1A inhibition than that of histone H3, suggesting
that substrate can affect E1A inhibition (Figures 1A andE1A Inhibits p300 Acetyltransferase Activity In Vitro
Since E1A inhibits both the p300/CBP and PCAF func- 1B). Quantitative analyses of the E1A inhibition of indi-
vidual histone H4 and H3 acetylation by p300 were,tions, we specifically investigated whether E1A inter-
feres with the HAT activity of both proteins. The effects therefore, carried out, and results are presented in Fig-
ures 1C and 1D, respectively. As shown in Figure 1C,of E1A on the p300-HAT activity are presented in Figure
1. In agreement with previous studies, p300 acetylates the addition of increasing amounts of E1A progressively
inhibited p300-mediated histone H4 acetylation. Higherhistones H4 and H3 (Figure 1A, lanes 2 and 6) (Ogryzko
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E1A concentration was, however, necessary for the inhi-
bition of histone H3 acetylation (Figure 1D). Under these
experimental conditions, the IC50 (inhibitory concentra-
tion for 50% reduction of the HAT activity) values of 1.6
mM for histone H4 and 8.4 mM for histone H3, respec-
tively, were obtained. While the biological significance
of this preference is unclear, we conclude that the nature
of the substrate as well as the abundance of E1A can
affect the outcome of the reaction.
The Carboxyl Terminus of E1A Is the HAT
Inhibitory Domain
Deletion mutants of E1A-13S protein were generated
to map the putative inhibitory domain. Since the E1A-
binding site and the HAT domain of p300/CBP are adja-
cent but do not overlap, we presumed the acetylase
inhibitory function in E1A would reside in a region dis-
tinct from the p300/CBP interaction domain. Three re-
gions of E1A termed CR1, CR2, and CR3 are conserved Figure 3. E1A Inhibits p300-Mediated p53 Acetylation
among various adenovirus serotypes (Kimelman et al., p300 (0.2 pmol) was preincubated with 2 pmol of E1A-13S (lane 2)
or E1A-13S-N185 (lane 3). Lane 1 is the control with buffer alone.1985). Previous mapping experiments demonstrated the
Following incubation, the mixture was used to acetylate 2 pmol ofN terminus (first 25 amino acids) and the adjacent CR1
recombinant p53. After separation of the sample by SDS-PAGE, theregion (amino acids 35±76) are necessary for p300 bind-
gel was stained with Coomassie brilliant blue (B), and acetylated
ing (Wang et al., 1993; Eckner et al., 1994). To determine p53 was detected by autoradiography (A). The positions of p53 and
whether the N-terminal 76 amino acids are also neces- E1A proteins are indicated.
sary for the inhibition of the p300-HAT activity, E1A mu-
tants lacking either the first 25 amino acids (E1A-13S-
E1A Inhibits p300-Mediated p53 AcetylationN25) or the first 76 amino acids (E1A-13S-N76) were
p300/CBP have also been shown to acetylate the non-generated (Figure 2). Surprisingly, both the N-terminal
histone substrate p53 and to regulate both its DNA bind-and CR1 deletion mutants retained potent HAT inhibitory
ing and transcriptional activities (Gu and Roeder, 1997;activity, similar to that of the wild-type protein (Figure
Gu et al., 1997). Additionally, p300 and p53 colocalize2A, right panel; compare constructs 2 and 3 with 1).
in a stable DNA-binding complex in the nucleus. Consis-While approximately 90% inhibition of histone H4 ace-
tent with these observations, E1A has been shown to
tylation was achieved with these deletion mutants, inhi-
repress the p53-mediated activation of the p21 and bax
bition of histone H3 acetylation, again, was weaker and
promoters and to reverse p53-mediated cell cycle arrest
varied between 50% and 80% (Figure 2A, right panel).
and apoptosis (Lill et al., 1997). These observations led
These results indicate that the first 76 amino acids of us to ask whether E1A also inhibits p300-mediated p53
E1A, known to be involved in p300 binding, are not acetylation. To examine this possibility, purified p300
required for the inhibition of the p300-HAT activity and and p53 were incubated in the presence or absence
suggest that the inhibitory activity may reside in other of E1A, and reaction products were analyzed. As with
E1A domains. Additional deletion mutants were, there- histones, p300-mediated p53 acetylation (Figure 3A,
fore, generated and used in inhibition assays to map lane 1) was severely inhibited by the E1A protein (lane
the HAT inhibitory domain. While the first N-terminal 120 2). In contrast, the E1A-13S-N185 mutant (Figure 2A)
amino acids were dispensable (construct 4), deletion of lacking the HAT inhibitory domain failed to inhibit p53
the CR2 and CR3 regions of E1A progressively elimi- acetylation (lane 3). Interestingly, we also observed par-
nated inhibition (constructs 5 and 6, respectively, and tial acetylation of E1A. The biological significance of
right panel). this acetylation is not clear at present, although it does
A series of complementary carboxy-terminal deletions indicate that the acetylation function is not completely
of E1A were also generated and tested for their ability disabled (see Figure 5). Nonetheless, we can conclude
to inhibit the p300-HAT activity (Figure 2B). As expected, both histone and nonhistone substrates are subject to
while the deletion of the carboxy-terminal 97 amino E1A inhibition.
acids had minimal effect (constructs 2 and 3, and right
panel), inhibitory activity was predominantly eliminated E1A Directly Binds to the Minimal HAT Domain
when the CR3, CR2, and the carboxyl terminus were of p300 and Inhibits Its Activity
deleted (constructs 4 and 5, and right panel). Consistent The cysteine-histidine-rich region 3 (CH3) of p300/CBP
with the results of Figure 2A, the N-terminal 76 amino (amino acids 1763±1811 of p300) is adjacent to the HAT
acids of E1A had little or no effect on the HAT activity domain and was previously shown to bind to the N
(construct 6, and right panel). These results localize the terminus of E1A (Eckner et al., 1994; Yang et al., 1996).
acetylase inhibitory function to the carboxyl terminus We, therefore, analyzed whether a p300 minimal HAT
of E1A that is distinct from the N-terminal p300/CBP- domain lacking the E1A-binding region (amino acids
1195±1761) remains sensitive to E1A inhibition in vitrobinding domain.
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Figure 4. E1A Interacts with the p300-HAT Domain and Inhibits Its Activity
(A) The p300-HAT domain is sensitive to E1A inhibition. HAT assays were carried out essentially as described in Figure 1A, except that the
minimal HAT domain of p300 was incubated alone (lane 1), with GST-E1A-13S (lane 2), or GST-E1A-13S-N76 (lane 3) prior to the addition of
histones. % inhibition of acetylation and % activity remaining (bottom panels) were calculated as described in Figure 1A.
(B) In vitro association of p300 and E1A. [35S]-labeled Gal4 fusion of p300 derivatives (lanes 1 and 5) were separately incubated with GST
(lanes 2 and 6), GST-E1A-13S (lanes 3 and 7), and GST-E1A-13S-N76 (lanes 4 and 8) affinity matrices. Following extensive washing, bound
proteins were eluted and resolved in a SDS-10% PAGE. Retained proteins were visualized by autoradiography. Input (lanes 1 and 5) represents
10% of the radiolabeled proteins used in binding reactions.
(Ogryzko et al., 1996). Surprisingly, the activity of the interactions may cooperate to inhibit p300 function in
vivo (see Figure 7).purified minimal HAT domain (Figure 4A, lane 1) was
severely inhibited (70%±95%; Figure 4A, bottom panel)
by the wild-type E1A-13S (lane 2), E1A-13S-N76 (lane E1A Directly Binds to the HAT Domain of PCAF
and Inhibits Its Activity3), and E1A-12S (data not shown). These results are
consistent with those of Figure 2 and demonstrate that While displacement of PCAF from p300 by E1A alone
has been suggested to block p300 function, this doesthe binding of the N terminus of E1A to the CH3 domain
of p300 is not essential for inhibition, suggesting E1A not explain how E1A also interferes with the PCAF-depen-
dent transcription (Yang et al., 1996; Puri et al., 1997).may directly interact with the HAT domain.
To test the above prediction, [35S]-labeled p300 deriv- We hypothesize that as with p300/CBP, E1A may also
bind to PCAF and diminish its HAT activity. To examineatives were incubated with the GST fusion of E1A-13S
proteins. As shown in Figure 4B, lane 3, when a p300 that hypothesis, inhibition studies on PCAF-mediated
acetylation reactions were carried out. Mononucleo-derivative containing the HAT and CH3 domains (amino
acids 1062±1963) was incubated with GST-E1A-13S, somes (MNS) as well as free histone H4 were incubated
separately with purified PCAF in the presence or ab-substantial binding was observed. This binding, as ex-
pected, was reduced (60%) but not completely elimi- sence of E1A derivatives and products analyzed. As
shown in Figure 5A, lanes 1 and 4, PCAF acetylatednated when E1A-13S-N76 was used as the GST affinity
matrix (lane 4). No binding, however, was observed with both free and nucleosomal histones (autoradiograph,
two left panels). As with free histones, acetylation ofthe GST matrix alone (lane 2). As predicted, we also
observed the binding of radiolabeled p300 minimal HAT MNS by PCAF was also severely inhibited (70%) by the
wild-type E1A protein (lanes 2 and 5). As expected, thedomain devoid of CH3 (amino acids 1195±1762), with
either GST-E1A-13S or GST-E1A-13S-N76 (lanes 7 and E1A-13S-N185 mutant (Figure 2A) had no effect (lanes
3 and 6). Interestingly, we also observed the acetylation8, respectively). These binding results are consistent
with the results of Figures 2 and 4A and extend the of GST-E1A-13S (lanes 2 and 5) and GST-E1A-13S-N185
(lanes 3 and 6), and as with p300 (Figure 3), the signifi-previous observation that CBP DCH3 still binds E1A
(Yang et al., 1996; Kurokawa et al., 1998). Together, cance of this acetylation is not clear.
A PCAF complex, free of p300 has recently been iso-these studies demonstrate E1A can physically interact
with and inhibit the activity of the minimal HAT domain lated and shown to acetylate both free and nucleosomal
histones (Ogryzko et al., 1998). Thus, it was importantof p300. It is, therefore, reasonable to speculate that
these multiple independent binding activities (via the to analyze whether the activity of the PCAF complex is
also affected by E1A. Lanes 1 and 8 of Figure 5B repre-CH3 and HAT domains of p300) might be mutually sup-
portive in the context of the E1A protein and that these sent acetylation of free histone H4 and MNS by the
Cell
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Figure 5. E1A Inhibits the HAT Activity of
Both Recombinant PCAF and the PCAF
Complex
(A) E1A inhibition of the HAT activity of recom-
binant PCAF. PCAF (5 pmol) was preincu-
bated with 30 pmol of E1A-13S (lanes 2 and
5) or E1A-13S-N185 (lanes 3 and 6). After in-
cubation, the mixtures were used to acetylate
15 pmol of histone H4 (lanes 1±3) or 30 pmol
of MNS (lanes 4±6). After separation of the
samples by SDS-PAGE, the gel was stained
with Coomassie brilliant blue (two right pan-
els), and acetylated proteins were detected
by autoradiography (two left panels). The po-
sitions of PCAF, E1A proteins, and histones
are indicated.
(B) E1A inhibition of the HAT activity of the
PCAF complex. PCAF complex (0.5 pmol)
was preincubated with 2 pmol (lanes 2 and
9; 5 and 12), 4 pmol (lanes 3 and 10; 6 and
13), or 8 pmol (lanes 4 and 11; 7 and 14) of
E1A-13S (lanes 2±4 and 9±11) or E1A-13S-
N185 (lanes 5±7 and 12±14). Lanes 1 and 8
are controls with buffer alone. After incuba-
tion, the mixtures were used to acetylate 5
pmol of histone H4 (lanes 1±7) or MNS (lanes
8±14). After separation of the products by
SDS-PAGE, acetylated proteins were de-
tected by autoradiography.
PCAF complex, respectively. The addition of increasing PCAF (E1A interaction domain 1 [EID1]; Figures 6A and
6C, lane 2). Although the deletion of the carboxy-termi-amounts of E1A progressively inhibited the activity of
the PCAF complex on both histone H4 (lanes 2±4) and nal 230 amino acids had little or no effect on binding
(Figure 6C, lanes 2, 4, 6, and 14), the deletion of the firstMNS (lanes 9±11). As expected, the E1A mutant lacking
the HAT inhibitory domain failed to inhibit the activity 521 amino acids (including EID1) of PCAF revealed a
second binding site, termed EID2 (Figures 6A and 6C,of the complex on either free histone H4 (lanes 5±7) or
MNS (lanes 12±14). These results show that like p300, lanes 8, 10, and 12). Interestingly, the EID2 (amino acids
521±601) encompasses the PCAF-HAT domain. Takenthe HAT activity of either the purified PCAF protein or the
PCAF complex, both of which are free of p300 activity, is together, these results suggest E1A, as with p300, may
disrupt the PCAF complex as well as inhibit its HATalso inhibited by E1A and suggest these two proteins
may physically interact. activity.
To address this possibility, [35S]-labeled PCAF was
incubated with the GST fusion of E1A derivatives, and E1A Inhibits p300-Dependent Transactivation In Vivo
It had previously been shown that p300/CBP functionbound proteins were analyzed. As shown in Figure 6B,
substantial retention of PCAF was observed with either as cofactors for nuclear hormone receptors and Stat1a
(Chakravarti et al., 1996; Zhang et al., 1996). Subse-full-length E1A or its derivatives that contain the first 60
amino acids (lanes 3 and 6±8). The deletion of the N quently, Korzus et al. have demonstrated the HAT activ-
ity of p300/CBP to be necessary for transcriptional acti-terminus and CR1 domains eliminated PCAF binding
(lanes 4 and 5) and tentatively localized the PCAF inter- vation by Stat1a but not for nuclear receptors (1998).
To demonstrate that the HAT inhibitory activity of E1Aaction domain to the same region where p300/CBP also
bind (PID, Figure 6A). is important for its ability to inhibit p300-dependent
transactivation in vivo, cell-based assays were per-We also mapped the E1A interaction domains in PCAF
(Figure 6C). For this purpose, in vitro labeled PCAF and formed. Eukaryotic expression constructs of the same
carboxyl-terminal (Figure 7A) and amino-terminal (Fig-its deletion mutants were incubated with GST-E1A and
bound proteins analyzed. As with p300/CBP, two bind- ure 7B) deletion mutants of E1A used in the in vitro
inhibition assays (Figure 2) were, therefore, generateding sites were found. The first is at the N terminus of
E1A Inhibits Acetyltransferase Activity
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Figure 6. E1A Directly Binds to PCAF
(A) Schematic representations of E1A and PCAF and the summary of analyses of the E1A and PCAF interaction domains. CR1 and CR2,
conserved regions 1 and 2, respectively; PID, PCAF interaction domain; EID1 and EID2, E1A interaction domains 1 and 2, respectively.
(B) Mapping of the PCAF interaction domain of EIA. [35S]-labeled PCAF (lane 1, Input) was incubated with either GST alone (lane 2) or various
GST-E1A derivatives as indicated (lanes 3±8).
(C) Mapping of the E1A interaction domains of PCAF. [35S]-labeled PCAF derivatives were incubated with GST-E1A as indicated. Binding
reactions for (B) and (C) were as described in Experimental Procedures. Bound proteins were separated by SDS-PAGE and visualized by
autoradiography. I, input, which represents 20% of the radiolabeled protein used in binding assays; B, bound.
and analyzed for their ability to repress either the Stat1a These results are consistent with the previous observa-
tions that the HAT activity of p300/CBP is necessary foror nuclear receptor activity. As shown in Figure 7A, lane
1, introduction of Stat1a into CV1 cells activated the Stat1a but not for the nuclear hormone receptor function
(Korzus et al., 1998). Taken together, these in vivo exper-expression of a luciferase reporter gene in the presence
of IFNg. As expected from the results of Figure 2, wild- iments demonstrate that while both the N-terminal as
well as the HAT inhibitory domains of E1A contribute totype as well as -C249 and -C192 mutants that still retain
CR2 and CR3 (the HAT inhibitory domain) strongly inhib- the inhibition of Stat1a, only the N terminus is necessary
for the block of nuclear receptor signaling, suggestingited the reporter gene activity (lanes 2±4). Interestingly,
progressive deletions of CR3 and CR2 eliminated the that multiple interactions may play important roles for
E1A action in vivo. Additionally, our results not onlyE1A-mediated inhibition (lanes 5 and 6). Surprisingly,
the -C79 mutant that still retains the previously shown emphasize multiple functions of E1A, but also reveal the
different contribution and dependency of the p300/CBPp300/CBP interaction domain failed to repress the re-
porter gene activity (lane 7). These results show that the and PCAF complexes to activation by different classes
of transcription factors.HAT inhibitory domain is necessary for E1A inhibition
of the p300-dependent Stat1a function in vivo.
Additional N-terminal deletion mutants of E1A were Discussion
utilized to determine the relative contribution of the N
terminus and the HAT inhibitory domain in the E1A- This work provides biochemical and functional evidence
that the E1A oncoprotein can inhibit the HAT activity ofmediated inhibition. As shown in Figure 7B, lanes 3 and
4, deletion of the first 76 amino acids partially eliminated both p300/CBP and PCAF and suggests that modulation
of acetylation may constitute a novel mechanism of tran-inhibition. However, additional deletion of CR2 and CR3
completely eliminated the inhibition (lanes 6 and 7). In scriptional control. Although E1A blocks both histone
H4 and H3 acetylation, it displays a pronounced prefer-contrast, in a parallel series of experiments, we found
the N-terminal region of E1A to be sufficient to block ence for histone H4 inhibition. While the basis for this
selective inhibition is not clear, biochemical and geneticnuclear hormone receptor function (data not shown).
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Figure 7. The HAT Inhibitory Domain Is Necessary for E1A Activity In Vivo
Left panels of (A) and (B) represent names and schematics of the wild-type E1A, C-terminal (A), and N-terminal (B) deletion mutants of E1A.
CV1 cells were transfected with a Stat1a expression vector, a luciferase reporter gene (lanes 1 of [A] and [B]), and E1A expression vectors
(lanes 2±7 of [A] and [B]) as shown in each figure. Following transfection, cells were incubated with IFNg for 8 hr. Cell extracts were prepared
and assayed for luciferase and b-galactosidase activities. Normalized reporter activity was calculated and plotted using the value of luciferase
activity of cell extracts transfected with no E1A as 100%.
studies suggest the acetylation of specific lysine resi- or overlapping region within p300/CBP. In the second
step, the C terminus of E1A acts to directly inhibit thedues of the histone H4 tail plays an important role in
transcription, which might also underlie E1A's preferen- HAT function. Therefore, the tethering of E1A via its N
terminus to p300/CBP or PCAF (step 1) enables thetial activity (Rundlett et al., 1998). Additionally, this inhi-
bition is not restricted to histones, as potent effects are C-terminal CR2 and CR3 regions to modulate the HAT
function (step 2). Additionally, the binding of E1A to thealso seen with a block of p53 acetylation. The physiologi-
cal relevance of this inhibition is strengthened by the N terminus of PCAF may strengthen the transcriptional
block, since p300/CBP also binds to the N terminus ofobservation that E1A blocks the activity of the PCAF
complex. These results in conjunction with the demon- PCAF. We speculate that, in aggregate, these interac-
tions cooperate to manifest the complete repressivestrated block of p300-dependent Stat1a signaling sug-
gest a potentially global role for E1A and acetylase inhi- activity of E1A in vivo.
In addition to associating with each other, p300/CBPbition in chromatin modification and transcriptional
regulation. and PCAF associate with numerous other costimulatory
proteins, which presumably results in the generation ofA combination of mapping and functional studies sug-
gests that E1A inhibition may occur in a two-step pro- a megacoactivation complex (Glass et al., 1997; Ogryzko
et al., 1998). On the assumption that these megacom-cess involving multiple independent but mutually coop-
erative interactions. First, as shown previously for p300 plexes act cooperatively, then disruption of the complex
formation might seem adequate to account for the inhib-and in Figure 6 for PCAF, the N-terminal 76 amino acids
of E1A mediate direct binding to either p300/CBP or itory effects of E1A. However, recent data suggest that
PCAF may act independently of p300/CBP, and thusPCAF. While this region does not inhibit the HAT activity,
it appears to be essential for disruption of the p300/ simple disruption of a p300 complex may not be suffi-
cient to ensure inhibition of all p300/CBP and PCAFCBP±PCAF complex in vivo. This disruption is a conse-
quence of the fact that E1A and PCAF bind to the same target gene activation. Even under such a scenario, the
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for 40 hr. Cells were harvested, washed with cold PBS, and lysedability of E1A to inhibit the HAT activity of the PCAF
by incubating in lysis buffer at 48C for 1 hr. Lysates were spun atcomplex assures p300/CBP-independent repression re-
45,000 rpm for 30 min and supernatants collected. A 1:1 slurry ofmains intact. Additionally, different roles for p300/CBP
monoclonal M2 anti-FLAG antibodies coupled to agarose beads in
and PCAF in muscle differentiation, cAMP signaling, and PBS (Kodak-IBI) was added to the supernatant and the mixture
hormonal activation and the E1A inhibition of these path- incubated for 1 hr at 48C. Beads were collected and washed with
lysis buffer extensively. Bound proteins were eluted with 200 ml ofways have also been demonstrated (Puri et al., 1997;
100 mg/ml of FLAG peptides. FLAG-tagged p53 was produced inKorzus et al., 1998; Kurokawa et al., 1998). Our results
Bac-to-Bac baculoviral expression system (GIBCO BRL) and wasprovide a pathway in which either p300/CBP or PCAF
used to infect SF9 cells. Following cell growth and harvest as de-signaling can be independently modulated, greatly
scribed above, recombinant p53 was affinity purified with mono-
broadening the domain of E1A effects. The generaliza- clonal M2 anti-FLAG antibody-immobilized agarose beads (Kodak-
tion of these effects to include a nonhistone substrate IBI). For bacterial and eukaryotic expression constructs of E1A-13S,
EIA212S, and their derivatives, the appropriate PCR-amplified frag-such as p53 further expands the arena of E1A action.
ments were cloned into pGex2TK and CMX-PL2 vectors, respec-The implications of our studies are several. First, our
tively. Proteins were expressed in BL21-DE3 E. coli cells and purifiedresults provide a novel mechanism of E1A action and
using glutathione sepharose affinity matrix. Purification methodsdelineate a novel transcriptional repressor function of
of recombinant PCAF and the PCAF complex were as described
the carboxyl half of the protein. Second, and perhaps previously (Yang et al., 1996; Ogryzko et al., 1998). Nucleosomes
more importantly, the mechanism of action of repression were isolated from HeLa cells as described previously (O'Neil et al.,
1992). Purified histones were purchased from Boehringer-Mann-is novel and establishes a block of the HAT activity as
heim. The purity of the proteins was routinely monitored by SDS-an additional mode of RNA polymerase II control. Third,
PAGE followed by Coomassie staining.this study provides evidence to explain the inhibitory
activity of E1A for transcription factors that do not de-
Acetylation Assays
pend on both p300/CBP and PCAF-HAT activity. These Unless otherwise mentioned, for standard histone acetylation
results help explain why E1A blocks Myo D function assays, purified p300 (200±500 ng) was mixed with either 1.2 mg of
during muscle differentiation, a process that does not histone H3 and H4 or 500 ng of individually purified histone H3 or
H4 (Boehringer-Mannheim) in a 25 ml reaction buffer containing 50require the p300/CBP-HAT activity (Puri et al., 1997).
mM Tris-HCl (pH 8.0), 10% glycerol, 0.1 mM EDTA, 0.1 mM PMSF,Finally, the ability of E1A to disrupt activation complexes
10 mM sodium butyrate, and 0.15 ml of [14C]-acetyl coenzyme A (50and to inhibit HAT activity are the properties that map
mCi/ml, 1000 pmol/ml) and incubated for 10 min at 308C followed by
to separable domains. Thus, E1A mutants can be used an additional 10 min incubation at 48C (Figures 1, 2, and 4). For
as valuable probes to study both HAT activity±depen- assays with p53, 0.2 pmol of p300 and 2 pmol of recombinant p53
dent and ±independent transcriptional processes. At were used (Figure 3). For assays with PCAF, 5 pmol of recombinant
PCAF were incubated with 15 pmol of histone H4 or 30 pmol ofthis stage the mechanism of inhibition of the HAT activity
MNS (Figure 5A). Acetylation assays with the PCAF complex con-remains obscure. It is possible that the regulation of
tained 0.5 pmol of the complex and 5 pmol of histone H4 or MNSacetylases would be analogous to that of kinases by
(Figure 5B). For E1A inhibition assays, p300, PCAF, or the PCAF
cellular kinase inhibitors (Serrano et al., 1993; Sherr and complex was incubated with specified amount of either E1A or its
Roberts, 1995). However, since there are no obvious derivative at 48C for 5 min prior to, during, or after the addition of
structural similarities among the tails of histones, p53, histones and [14C] acetyl coenzyme A as described in the figure
legends. Otherwise, in all standard inhibition assays approximatelyand E1A, this possibility remains purely speculative. In
7±10 mg of purified GST fusion of E1A or its derivatives, whichthe future, it will be important to determine whether other
represent a 1:1 to 2:1 molar ratio to histones, were used. Reactioncoactivation/HAT complexes, including the SAGA, p300,
products were separated in polyacrylamide-SDS gel (BioRad), visu-
and TFIID complexes as well as other nonhistone sub- alized, and quantified by phosphor-imager or autoradiography.
strates, are also sensitive to E1A inhibition (Mizzen et
al., 1996; Imhof et al., 1997; Grant et al., 1998; Naar GST Pull-Down Assays
et al., 1998). Additionally, we suggest that other viral [35S]-labeled Gal4-p300-1062-1963 or Gal4-p300-1195-1762 was in-
cubated separately with the GST, GST-E1A-13S, or GST-E1A-13S-proteins (e.g., SV40 large T antigen) could have similar
N76 protein bound to glutathione sepharose beads for 1 hr at 48C.activity, which leads to the intriguing speculation that
Following extensive washing, eluted proteins were separated bycellular factors with corresponding activities may exist.
SDS-10% PAGE and analyzed by autoradiography (Figure 4). In vitro
In conclusion, our work demonstrates that the acetyl- binding assays with PCAF were carried out by incubating matrix-
transferase activity of coactivators can be modulated bound GST fusions of E1A with [35S]-labeled PCAF derivatives at
and thus reveals a novel pathway for controlling hor- 258C for 30 min followed by extensive washes. Bound proteins were
separated by SDS-12.5% PAGE and visualized by autoradiographymonal signaling by modulating RNA polymerase II tran-
(Figure 6).scription (Barlev et al., 1998).
Transfection Assays
CV1 cells were transiently transfected in triplicates in 48-well platesExperimental Procedures
with 2 3 104 cells/well using lipofection/DOTAP method (Boehringer-
Mannheim). The following amounts of DNAs were used per well:Plasmids and Proteins
Gal4-p300 derivatives were generated by cloning the appropriate 3Xly6E-Luciferase reporter (20 ng), CMX-b-galactosidase internal
control (60 ng), CMV-Stat1a (10 ng), and various CMX-E1A expres-PCR-amplified p300 fragments into CMX-Gal4N vector (Chakravarti
et al., 1996). PCR-amplified PCAF fragments were cloned into sion vectors (1.5 ng for Figure 7A and 6 ng for Figure 7B, respectively)
as described in the figure. Five hours after transfection, cells wereCAN(N) vector. In vitro radiolabeled p300 and PCAF proteins were
synthesized using appropriate plasmids in TNT-coupled reticulocyte treated with IFNg for 8 hr. Lysate from each sample was prepared,
and luciferase activity was determined and normalized by the levellysates system (Promega). For the purification of FLAG-tagged p300
and its derivative, SF9 cells were grown to 80% confluence in five of b-galactosidase. Relative normalized reporter activity was plotted
using the value of the luciferase activity of extracts prepared from150 mm tissue culture dishes, infected either with recombinant p300
baculovirus or p300 amino acids 1195±1761 baculovirus and grown cells transfected without any E1A expression vector as 100%. (IFNg,
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IFNg-responsive 3Xly6E-GAS-Luc reporter, and CMV-Stat1a ex- Janknecht, R., and Hunter, T. (1996). A growing coactivator network.
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